Monitoring of Safety of Home-made Subcutaneous Bortezomib by CHPS

doi:10.19803/j.1672-8629.2020.12.14

Abstract

Abstract: Objective To monitor adverse drug events (AE) induced by home-made bortezomib for subcutaneous injection using the Chinese hospital pharmacovigilance system (CHPS).Methods Thirty-two cases involving the use of home-made bortezomib injected subcutaneously of Guiyang first people's Hospital from January to June 2019 were selected by the CHPS, and all the AE were calculated manually. Combined with the AE listed in the specifications of imported drugs, the drug trial evaluation scheme in the CHPS was formulated. Finally, all the AE related to the 32 cases were screened by the scheme, and the numbers of AE obtained by the two methods were compared.Results The positive rate of the CHPS was 73.07% (20 items), and 100% in 6 items. There was no significant difference between the two groups(P>0.05).Conclusion The drug test evaluation scheme in the CHPS is applicable to the detection of home-made bortezomib AE for subcutaneous injection, but it still needs to be further improved.

Key words: Chinese hospital pharmacovigilance system, adverse drug event, bortezomib, home-made drugs, safety

CLC Number:

R994.1R979.1

PAN Daowei, WAN Lei. Monitoring of Safety of Home-made Subcutaneous Bortezomib by CHPS[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 913-916.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.2020.12.14

https://www.zgywjj.com/EN/Y2020/V17/I12/913

References

[1] Huang GH,Du HR,Gong LK.Analysis of the international research situation of pharmacovigilance in the past five years and its enlightenment to China[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2018,15(5):268-275.
[2] Hou YF,Song HB,Liu HL,et al.Practice and discussion of active monitoring based on Chinese hospital drug alert system[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(4):212-214.
[3] NCCN Clinical Practice Guidelines in Oncology(NCCN guidelines):Multiple Myeloma.Verion 2.0[EB/OL].2009[2019-06-25].https://www.nccn.org/patients
[4] State Food and Drug Administration.Technical guidelines for research and development and evaluation of biosimilars[EB/OL].Beijing:State Food and Drug Administration.(2015-02-28)[2019-06-25].https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20150228155701114.html.
[5] Kurutkan MN,Usta E,Orhan F,et al.Application of the IHI Global Trigger Tool in measuring the adverse event rate in a Turkish healthcare setting[J].The International Journal of Risk &Safety in Medicine,2015,27(1):11-21.
[6] Carnevali L,Krug B,Amant F,et al.Performance of the Adverse Drug Event Trigger Tool and the Global Trigger Tool for Identifying Adverse Drug Events:Experience in a Belgian Hospital[J].Annals of Pharmacotherapy,2013,47(11):1414-1419.
[7] Griffin FA,Resar RK.IHI Global Trigger Tool for Measuring Adverse Events (Second Edition)[M].IHI Innovation Series white paper.Cambridge,Massachusetts:Institute for Healthcare Improvement,2009:18-29.
[8] National Institutes of Health National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0[M].U.S.Department of Health and Human Services Published:November 27,2017.
[9] FDA.Labeling for Biosimilar Products[EB/OL].(2018-07-18)[2019-06-25].https://www.fda.gov/media/96894/download.
[10] Bertrand Arnulf,Halyna Pylypenko,Sebastian Grosicki,et al.Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma[J].Haematologica,2012,97(12):1925-1928.

[1]	SU Hai, ZAN Mengqing, NIU Jianzhao, MA Lingyun, LIU Qian. Effect of ethanol on release behavior of glipizide controlled release tablets by HPLC [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 638-643.
[2]	PAN Zhiyu, ZHU Jian, YU Yanan, LIU Jun, JIANG Yanhua, QIAN Zhenzhen, WU Guang, WANG Zhong, WU Hongli, JING Zhiwei. A real-world safety study of 3 010 cases of Qizhitongluo capsule [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 660-665.
[3]	SHAO Bo, XU Lili, ZHU Lan, LIU Shuo, WAN Hao, HUANG Guangrui. Risks of liver injury caused by Shiduqing preparations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 666-670.
[4]	SHI Guanhong, WANG Qi, SUN Hao, CHEN Yanjie, CHU Ziyan, JIANG Ao, TANG Zaixiang, LIU Jingfang. Safety signal analysis of antidepressants use in fetus and neonate based on US FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 687-692.
[5]	WANG Chunnan, QIN Shiru, ZHANG Meng, SONG Haibo, LIU Junchang, LI Ge, SUN Feng. Evaluation of drug safety with multicenter real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 703-708.
[6]	CAO Ying, ZHOU Huziwei, ZHU Lan, WANG Shengfeng. Management of compound glycyrrhiza oral solution and recommendations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 529-534.
[7]	YU Jing, PALATI Reheman, ZHAO Ting, FENG Jirong, SUN Yan, HE Lei. Correlation of the efficacy, safety and plasma concentration of lacosamide in the treatment of children with epilepsy under 4 years of age [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 559-562.
[8]	LIU Cuili, WU Chen, WANG Tao. Risks of piracetam preparations to safety [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 563-566.
[9]	SU Xiaohan, ZENG Jiao, LI Xue, LIU Lixin, HOU Lingmi, LI Jinsui. Adverse events of abemaciclib in breast cancer patients based on US FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 580-586.
[10]	YANG Bo, WANG Mengjiao, HU Lili, WANG Laicheng, LI Qian, KONG Feifei, LYU Dongmei, SHEN Jiani. Safety assessment and risk factor analysis of PD-1 immunotherapy in a cohort of 385 patients [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 447-450.
[11]	LI haiyan, YANG Zhongxu, LIU Yuekun, WANG Lihong. Pharmaceutical care of serious adverse reactions due to methotrexate treatment of ectopic pregnancy [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 454-456.
[12]	GU Xiaotong, SUN Xuelin, ZHENG Li. Pharmacological effect and clinical evaluation of rezafungin in treating candidemia and invasive candidiasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 469-472.
[13]	ZHANG Chenxue, PEI Yusheng, CAI Tong. Research progress in bacterial endotoxin test methods for insoluble raw materials, excipients and preparations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 273-279.
[14]	LIU Yi, QIN Ling, GUO Xianhui, CHEN Hua, PEI Yusheng. Applications of TGA and DSC in pharmaceutical analysis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 283-289.
[15]	ZHANG Xiaoming, LYU Ping, HU Xinyue, DING Xiaoli, LI Jing, LIANG Chenggang. Detection of single-chain precursor residues in insulin glargine by ELISA [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 290-294.